GG genotype may increase severity of multiple sclerosis symptoms: Study

A new study shows a gene variant may increase the severity of multiple sclerosis (MS) symptoms. The research will be published in the August 3, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.

For the study, researchers screened the oligoadenylate synthetase (OAS1) gene in 401 people with MS, 394 people without MS and 178 people receiving the MS treatment beta interferon.

On the analysis of the OAS1 gene, 63 percent of people with MS had the AA genotype compared to 57 percent of people without MS. The GG genotype was found in 37 percent of people with MS compared to 43 percent of people without the disease.

While the OAS1 gene was weakly associated with disease susceptibility, the study found that people who had the AA genotype had earlier relapses and increased disease activity compared to those without the genotype.

"While we don't understand why some patients vary so widely in their disease activity, this genetic association may give us clues to help direct future research," said study author Margaret O'Brien, PhD, with St. Vincent's University Hospital in Dublin, Ireland.

The study also found people who had the GG genotype had less disease activity and fewer relapses. "It's possible that the GG genotype may protect against increased disease activity in people with MS, but more research is needed," said O'Brien.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Multiple sclerosis drug could help individuals with reduced working memory